Insilico initiates phase III clinical trial for rentosertib, its AI-empowered TNIK inhibitor for idiopathic pulmonary fibrosis

Insilico initiates phase III clinical trial for rentosertib, its AI-empowered TNIK inhibitor for idiopathic pulmonary fibrosis EurekAlert!